Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Allogeneic MSCs in Pediatric Inflammatory Bowel Disease
NCT02150551Phase 1Completed
- Sponsor
- Catherine Bollard
- Start
- Jun 2018
- Primary completion
- Sep 2018
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label trial of allogeneic bone marrow-derived mesenchymal stromal cells in Crohn's disease and ulcerative colitis (UC), sponsored by Catherine Bollard. Primary endpoint: Number of Subjects Who Experience Serious Adverse Events, Adverse Events, and/or Early Treatment Discontinuations. Started Jun 2018; status: completed.
02
Drugs
allogeneic bone marrow-derived mesenchymal stromal cells
03
Conditions
Crohn's diseaseulcerative colitis (UC)
Beyond the preview
Go deeper on NCT02150551.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02150551.